CRF01-AE subtype is associated with X4 tropism and fast HIV progression in Chinese patients infected through sexual transmission

AIDS

Volumn 28, Issue 4, 2014, Pages 521-530

  Li, Yijia ^a   Han, Yang ^a   Xie, Jing ^a   Gu, Lijun ^b,c   Li, Wenjuan ^d   Wang, Huanling ^a   Lv, Wei ^a   Song, Xiaojing ^a   Li, Yanling ^a   Routy, Jean Pierre ^e   Ishida, Takaomi ^b,c   Iwamoto, Aikichi ^b,c   Li, Taisheng ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b UNIVERSITY OF TOKYO   (Japan)

^c INSTITUTE OF MICROBIOLOGY   (China)

^d CAPITAL MEDICAL UNIVERSITY   (China)

^e MCGILL UNIVERSITY   (Canada)

Author keywords

CRF01 AE; HIV; HIV progression; MSM; X4 tropism

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; ARTICLE; CD4 LYMPHOCYTE COUNT; CHINESE; DISEASE COURSE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LENTIVIRINAE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOLECULAR EPIDEMIOLOGY; PRIORITY JOURNAL; RISK ASSESSMENT; SEROCONVERSION; SEXUAL TRANSMISSION; VIRAL TROPISM; VIRUS LOAD; VIRUS STRAIN; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; SEQUENCE ANALYSIS, DNA; TIME; VIRAL TROPISM; YOUNG ADULT;

EID: 84893338556     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000125     Document Type: Article

References (41)

1. Langford SE, Ananworanich J, Cooper DA. Predictors of disease progression in HIV infection: A review. AIDS Res Ther 2007; 4:11.
2. Koot M, Keet IP, Vos AH, De Goede RE, Roos MT, Coutinho RA, et al. Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4R cell depletion and progression to AIDS. Ann Intern Med 1993; 118:681-688.
3. Wilkin TJ, Su Z, Kuritzkes DR, Hughes M, Flexner C, Gross R, et al. HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. Clin Infect Dis 2007; 44:591-595.
4. Baeten JM, Chohan B, Lavreys L, Chohan V, McClelland RS, Certain L, et al. HIV-1 subtype D infection is associated with faster disease progression than subtype A in spite of similar plasma HIV-1 loads. J Infect Dis 2007; 195:1177-1180.
5. Vasan A, Renjifo B, Hertzmark E, Chaplin B, Msamanga G, Essex M, et al. Different rates of disease progression of HIV type 1 infection in Tanzania based on infecting subtype. Clin Infect Dis 2006; 42:843-852.
6. Keller M, Lu Y, Lalonde RG, Klein MB. Impact of HIV-1 viral subtype on CD4R T-cell decline and clinical outcomes in antiretroviral naive patients receiving universal healthcare. AIDS 2009; 23:731-737.
7. Lau KA, Wang B, Saksena NK. Emerging trends of HIV epidemiology in Asia. AIDS Rev 2007; 9:218-229.
8. Han X, Dai D, Zhao B, Liu J, Ding H, Zhang M, et al. Genetic and epidemiologic characterization of HIV-1 infection in Liaoning Province, China. J Acquir Immune Defic Syndr 2010; 53:S27-S33.
9. Chen JH, Wong KH, Li P, Chan KC, Lee MP, Lam HY, et al. Molecular epidemiological study of HIV-1 CRF01-AE transmission in Hong Kong. J Acquir Immune Defic Syndr 2009; 51:530-535.
10. Zhang Y, Lu L, Ba L, Liu L, Yang L, Jia M, et al. Dominance of HIV-1 subtype CRF01-AE in sexually acquired cases leads to a new epidemic in Yunnan province of China. PLoS Med 2006; 3:e443.
11. Hu DJ, Vanichseni S, Mastro TD, Raktham S, Young NL, Mock PA, et al. Viral load differences in early infection with two HIV-1 subtypes. AIDS 2001; 15:683-691.
12. Rangsin R, Piyaraj P, Sirisanthana T, Sirisopana N, Short O, Nelson KE. The natural history of HIV-1 subtype E infection in young men in Thailand with up to 14 years of follow-up. AIDS 2007; 21:S39-S46.
13. Rangsin R, Chiu J, Khamboonruang C, Sirisopana N, Eiumtrakul S, Brown AE, et al. The natural history of HIV-1 infection in young Thai men after seroconversion. J Acquir Immune Defic Syndr 2004; 36:622-629.
14. Ng KY, Chew KK, Kaur P, Kwan JY, Khong WX, Lin L, et al. High prevalence of CXCR4 usage among treatment-naive CRF01-AE and CRF51-01B-infected HIV-1 subjects in Singapore. BMC Infect Dis 2013; 13:90.
15. Chalmet K, Dauwe K, Foquet L, Baatz F, Seguin-Devaux C, Van Der Gucht B, et al. Presence of CXCR4-using HIV-1 in patients with recently diagnosed infection: Correlates and evidence for transmission. J Infect Dis 2012; 205:174-184.
16. De Silva UC, Warachit J, Sattagowit N, Jirapongwattana C, Panthong S, Utachee P, et al. Genotypic characterization of HIV type 1 env gp160 sequences from three regions in Thailand. AIDS Res Hum Retroviruses 2010; 26:223-227.
17. Menu E, Reynes JM, Muller-Trutwin MC, Guillemot L, Versmisse P, Chiron M, et al. Predominance of CCR5-dependent HIV-1 subtype E isolates in Cambodia. J Acquir Immune Defic Syndr Hum Retrovirol 1999; 20:481-487.
18. The Ministry of Health of the Peoples Republic of China/UNAIDS/WHO. 2012 China AIDS Response Progress Report. http://www.unaids.org/en/dataanalysis/ knowyourresponse/countryprogressreports/2012countries/ce-CN-Narrative-Report [1].pdf. [Accessed 27 July 2013].
19. Zhang Z, Wu Z, Poundstone KE, Yin W, Pang L, Rou K, et al. Unprotected sex among HIV-positive treatment-seeking opioid-dependent adults in China: A cross-sectional study. Sex Transm Dis 2012; 39:930-937.
20. Zhang F, Dou Z, Ma Y, Zhang Y, Zhao Y, Zhao D, et al. Effect of earlier initiation of antiretroviral treatment and increased treatment coverage on HIV-related mortality in China: A national observational cohort study. Lancet Infect Dis 2011; 11:516-524.
21. Siegfried N, Uthman OA, Rutherford GW. Optimal time for initiation of antiretroviral therapy in asymptomatic, HIVinfected, treatment-naive adults. Cochrane Database Syst Rev 2010:CD008272.
22. Smith K, Powers KA, Kashuba AD, Cohen MS. HIV-1 treatment as prevention: The good, the bad, and the challenges. Curr Opin HIV AIDS 2011; 6:315-325.
23. CASCADE Collaboration (Concerted Action on SeroConversion to AIDS Death in Europe). Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: A collaborative re-analysis. Lancet 2000; 355:1131-1137.
24. Schneider E, Whitmore S, Glynn KM, Dominguez K, Mitsch A, McKenna MT. Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged 26.Wang H, Li Y, Zhang C, Han Y, Zhang X, Zhu T, et al.Immunological and virological responses to cART in HIV/HBV co-infected patients from a multicenter cohort.AIDS2012;26:1755-1763
25. Wang H, Li Y, Zhang C, Han Y, Zhang X, Zhu T, et al. Immunological and virological responses to cART in HIV/HBV co-infected patients from a multicenter cohort. AIDS 2012; 26:1755-1763.
26. Lengauer T, Sander O, Sierra S, Thielen A, Kaiser R. Bioinformatics prediction of HIV coreceptor usage. Nat Biotechnol 2007; 25:1407-1410.
27. Raymond S, Delobel P, Rogez S, Encinas S, Bruel P, Pasquier C, et al. Genotypic prediction of HIV-1 CRF01-AE tropism. J Clin Microbiol 2013; 51:564-570.
28. Mulinge M, Lemaire M, Servais JY, Rybicki A, Struck D, Da Silva ES, et al. HIV-1 tropism determination using a phenotypic Env recombinant viral assay highlights overestimation of CXCR4-usage by genotypic prediction algorithms for CRRF01-AE and CRF02-AG. PLoS One 2013; 8:e60566.
29. Lole KS, Bollinger RC, Paranjape RS, Gadkari D, Kulkarni SS, Novak NG, et al. Full-length human immunodeficiency virus type 1 genomes from subtype C-infected seroconverters in India, with evidence of intersubtype recombination. J Virol 1999; 73:152-160.
30. Crum-Cianflone N, Eberly L, Zhang Y, Ganesan A, Weintrob A, Marconi V, et al. Is HIV becoming more virulent Initial CD4 cell counts among HIV seroconverters during the course of the HIV epidemic: 1985-2007. Clin Infect Dis 2009; 48:1285-1292.
31. Dorrucci M, Rezza G, Porter K, Phillips A. Temporal trends in postseroconversion CD4 cell count and HIV load: The Concerted Action on Seroconversion to AIDS and Death in Europe Collaboration, 1985-2002. J Infect Dis 2007; 195:525-534.
32. Wang W, Jiang S, Li S, Yang K, Ma L, Zhang F, et al. Identification of subtype B, multiple circulating recombinant forms and unique recombinants of HIV type 1 in an MSM cohort in China. AIDS Res Hum Retroviruses 2008; 24:1245-1254.
33. Lin H, He N, Zhou S, Ding Y, Qiu D, Zhang T, et al. Behavioral and molecular tracing of risky sexual contacts in a sample of Chinese HIV-infected men who have sex with men. Am J Epidemiol 2013; 177:343-350.
34. Zhang C, Xu S, Wei J, Guo H. Predicted co-receptor tropism and sequence characteristics of China HIV-1 V3 loops: Implications for the future usage of CCR5 antagonists and AIDS vaccine development. Int J Infect Dis 2009; 13:12.
35. Philpott SM. HIV-1 coreceptor usage, transmission, and disease progression. Curr HIV Res 2003; 1:217-227.
36. Ng OT, Lin L, Laeyendecker O, Quinn TC, Sun YJ, Lee CC, et al. Increased rate of CD4R T-cell decline and faster time to antiretroviral therapy in HIV-1 subtype CRF01-AE infected seroconverters in Singapore. PLoS One 2011; 6:e15738.
37. Breaux K, Gadde S, Graviss EA, Rodriguez-Barradas MC. One year survival of HIV-infected veterans with CD4 <100 cells/mm3: Data from a veteran cohort AIDS Care 2010 22 886-894
38. National Antiretroviral Treatment Manual (3rd edition). National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, 2012. [In Chinese]. http://www.chain.net.cn/document/ 20120905162017665677.pdf. [Accessed 18 July 2013].
39. Mann B, Milloy MJ, Kerr T, Zhang R, Montaner J, Wood E. Improved adherence to modern antiretroviral therapy among HIV-infected injecting drug users. HIV Med 2012; 13:596-601.
40. Gonzalez A, Mimiaga MJ, Israel J, Andres Bedoya C, Safren SA. Substance use predictors of poor medication adherence: The role of substance use coping among HIV-infected patients in opioid dependence treatment. AIDS Behav 2013; 17:168-173.
41. Murray M, Hogg RS, Lima VD, May MT, Moore DM, Abgrall S, et al. The effect of injecting drug use history on disease progression and death among HIV-positive individuals initiating combination antiretroviral therapy: Collaborative cohort analysis. HIV Med 2012; 13:89-97.